Artelo Biosciences To Present Preclinical Data Showcasing Research On ART26.12 And ART12.11 In Anxiety And Depression At Neuroscience 2023
Portfolio Pulse from Benzinga Newsdesk
Artelo Biosciences, Inc. (NASDAQ:ARTL) will present preclinical data on ART26.12 and ART12.11, potential treatments for anxiety and depression, at Neuroscience 2023. The company plans to file an IND application with the FDA in the first half of 2024 to develop ART26.12 for the treatment of neuropathic pain. ART26.12 has shown positive effects in animal models of painful neuropathies, including chemotherapy-induced peripheral neuropathy and diabetic neuropathy.
November 02, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Artelo Biosciences will present preclinical data on potential treatments for anxiety and depression, and plans to file an IND application with the FDA for a neuropathic pain treatment. This could potentially boost investor confidence in the company's research and development capabilities.
The announcement of Artelo Biosciences presenting preclinical data at a major conference and planning to file an IND application with the FDA indicates progress in their research and development. This could potentially lead to increased investor confidence and a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100